-
11.13.2024 | Seres Therapeutics reports third quarter 2024 financial results and provides business updates
SER-155 Phase 1b placebo-controlled clinical results demonstrated significant reduction in both bacterial bloodstream infections and systemic antibiotic exposure, as well as lower incidence of febrile neutropenia, as compared to placebo, through day 100 post allo-HSCT.
-
11.11.2024 | La lucha contra la neumonía y la resistencia a los antibióticos: Vaxdyn y el candidato a vacuna K-Vax frente a ‘Klebsiella pneumoniae’
Con motivo del Día Mundial contra la Neumonía entrevistamos a Juanjo Infante, consejero delegado de Vaxdyn, biotecnológica desarrolladora del candidato a vacuna K-Vax frente a Klebsiella pneumoniae, responsable de uno de los tipos de neumonía más graves.
-
11.07.2024 | Wir preschen voran
gibt sich Mark Brönstrup optimistisch. Das von ihm geleitete Start-up-Projekt PROTON entwickelt – mit taktischem Kalkül – Inhibitoren von Bakterientoxinen.
-
10.31.2024 | David Veitch – CEO, Basilea Pharmaceutica
David Veitch, the CEO of Basilea Pharmaceutica, shares his insights into the company's strategic vision to become a global leader in the antifungal and antibacterial space.
-
10.24.2024 | ‘Low risk’ antibiotic has led to an almost untreatable superbug
A new study has found that an antibiotic for liver disease patients could expose them to greater risk of a dangerous superbug.
-
10.22.2024 | Nodenza Venture Partners invests in Trellis Bioscience
Nodenza Venture Partners today announces its investment in Trellis Bioscience, a clinical-stage company focused on discovering and developing native human monoclonal antibodies to treat and prevent drug-resistant, life-threatening infectious diseases.
-
10.21.2024 | Research Roundup: Marburg treatment trial, AMR innovation funding, Shigella vaccine development
Valneva and LimmaTech announced last week that their Shigella4V (S4V) vaccine has been awarded Fast Track designation by the US Food and Drug Administration.
-
10.18.2024 | IDWeek spotlights new rapid ID diagnostics in the pipeline
Three promising new rapid infectious disease diagnostic assays took the stage at IDWeek 2024, in Los Angeles, including the PhAST blood culture gram-negative (BC GN) assay, deepull UllCORE BSI Test and Day Zero Diagnostics (DZD) Pathovate ultra-high enrichment (UHE).
-
10.16.2024 | Vedanta Biosciences to present at IDWeek 2024 on benefit of VE303 on antibiotic resistant gene levels in patient microbiomes
Vedanta Biosciences, a late clinical-stage company developing defined bacterial consortia as oral therapies with an initial focus on gastrointestinal diseases, today announced the oral presentation of additional analyses from its completed Phase 2 CONSORTIUM study of VE303, an orally administered defined bacterial consortium candidate that is being developed for the prevention of recurrent Clostridioides difficile infection (rCDI).
-
10.08.2024 | Comisión Europea y Bill Gates, entre los inversores que apoyan con 38 millones a Vaxdyn para su vacuna
La empresa biotecnológica sevillana Vaxdyn hará en 2025 el primer ensayo clínico de su vacuna contra una de las bacterias que más muertes causa en el mundo por infecciones.
-
10.03.2024 | Vedanta Biosciences founder and CEO Bernat Olle shares an expert take on microbiome drug development
He describes how Vedanta is isolating specific bacterial strains and using them as a defined composition for its medicines, and why he thinks that is important.
-
10.02.2024 | Combating AMR With Antibiotic Development Incentives
There are a number of issues associated with antibiotic development including, the lifespan of antibiotics’ effectiveness, the time it takes to develop new therapies, and reimbursement.
-
09.19.2024 | BWC0977 presents a new approach to addressing antimicrobial resistance
The global crisis of antimicrobial resistance (AMR) necessitates the urgent development of broad-spectrum antibacterial drugs that can effectively combat multi-drug resistant (MDR) pathogens.
-
09.12.2024 | Seres Therapeutics reports SER-155 phase 1b placebo-controlled cohort 2 study safety and clinical results in patients undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT)
SER-155 administration was associated with a significant reduction in both bacterial bloodstream infections (BSIs) and systemic antibiotic exposure, as well as lower incidence of febrile neutropenia, as compared to placebo through day 100 post HSCT.
-
09.03.2024 | Vaxcyte shares boom as one of biotech’s big David vs. Goliath stories heats up
With new vaccine data released Tuesday, Vaxcyte, a San Carlos, Calif.-based firm, emerged as one of biotechnology’s hottest David-vs.-Goliath stories as the company seeks to challenge one of Pfizer’s biggest franchises: the Prevnar vaccine against pneumococcal disease.
-
09.02.2024 | Vaxdyn consigue 14.5 millones del EIC Accelerator para financiar la entrada en fase clínica de su plataforma de vacunas
Gracias al apoyo de la aceleradora internacional CARB-X e inversores privados, Vaxdyn, con sede en Sevilla, ha logrado construir un paquete preclínico que ha validado su tecnología única de vacunas contra las principales bacterias resistentes a antibióticos.
-
08.12.2024 | Locus Biosciences announces positive results from part 1 of ELIMINATE phase 2 trial of the engineered bacteriophage therapy LBP-EC01 published in The Lancet Infectious Diseases
Locus Biosciences, Inc. (“Locus”), a clinical-stage biotechnology company developing a new class of precision engineered bacteriophage treatments for a diverse set of bacterial diseases, today announced positive results from Part 1 of its two-part Phase 2 ELIMINATE trial.
-
08.06.2024 | Q&A: Biologic drugs are reinvented to treat infectious diseases
A biotechnology company has re-invented how biologic drugs are invented by using the patented technology to use the food algae spirulina to deliver therapeutic proteins. To learn more, Digital Journal spoke with Lumen Bioscience Co-Founder and CEO, Brian Finrow.
-
08.01.2024 | GenomeKey awarded $11.4M to transform sepsis diagnosis and treatment
GenomeKey has been awarded a major grant from Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) to build a functioning, automated prototype of their desktop diagnostic device.
-
07.31.2024 | Industry disruptors: These companies are leading the way
With the influx of technological advancements and evolving customer expectations, some companies are not just a part of their industry; they are completely disrupting it. These companies are making a difference with their innovative approach and bold business model.
-
07.31.2024 | GenomeKey awarded $11.4M to transform sepsis diagnosis and treatment
GenomeKey has been awarded a major grant from Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) to build a functioning, automated prototype of their desktop diagnostic device.
-
07.19.2024 | With portable PCR platform, Prompt Dx aims to expand STI treatment options
Against a backdrop of increased drug resistance that has made treating patients with gonorrhea more challenging, Prompt Diagnostics aims to deliver portable PCR-based tests to quickly give clinicians drug susceptibility information that could expand treatment options.
-
07.16.2024 | GSK CEO and Fleming Initiative Chair on fighting drug-resistant ‘superbugs’
Emma Walmsley, CEO of GSK and Ara Darzi, Executive Director of the Fleming Initiative and Imperial College's Director of the Institute of Global Health Innovation, on their efforts to combat the rise of antimicrobial resistance.
-
07.16.2024 | Trellis Bioscience’s TRL1068 study published in AAC: A breakthrough in AMR
Trellis Bioscience, Inc. is excited to announce the peer-reviewed publication of the results of a landmark clinical study in a leading infectious disease journal, Antimicrobial Agents and Chemotherapy (AAC), from the American Society of Microbiology on July 16, 2024.
-
07.12.2024 | GenomeKey and Oxford Nanopore Technologies collaborate
GenomeKey and Oxford Nanopore Technologies have announced a collaboration to develop a new diagnostic tool for bloodstream infections that has the potential to be transformative in the battle against sepsis.
-
07.11.2024 | Doherty Institute enters strategic partnership with DFAT to tackle infectious diseases in the region
Improving equitable health outcomes by anticipating, preventing, detecting and controlling infectious diseases across the Pacific and South East Asia is the objective of a new program of work to be conducted by the Doherty Institute thanks to a new strategic partnership with the Department of Foreign Affairs and Trade (DFAT).
-
07.01.2024 | LimmaTech appoints Staph Leavenworth Bakali as Chairman of the Board
LimmaTech Biologics AG, a clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases, today announced the appointment of Staph Leavenworth Bakali as independent Chairman of its Board of Directors. Mr. Leavenworth Bakali brings over 30 years of senior executive and board-level experience in the life science and healthcare industries.
-
06.28.2024 | CARB-X awards $1M each to Prompt Diagnostics, Fuse Diagnostics for point-of-care STI tests
The nonprofit organization Combatting Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) announced on Thursday that it has awarded $1 million to Prompt Diagnostics for the development of a portable multiplex testing platform and a test that could be used to detect the pathogen that causes gonorrhea and characterize the pathogen's drug susceptibility.
-
06.28.2024 | SNIPR Biome receives funding for the development of CRISPR-medicines to improve Environmental Enteric Dysfunction (EED) in pregnant women
SNIPR Biome, a pioneer in the development CRISPR-Cas armed phages (CAPs) to prevent and treat bacterial infections, announced today that it has received funding from the Bill & Melinda Gates Foundation to develop a microbiome-directed intervention designed to improve environmental enteric dysfunction (EED) by reducing gut entero-pathogen burden in pregnant women from low- and middle-income countries (LMICs).
-
06.27.2024 | CARB-X awards $1 million for rapid diagnostic for drug-resistant gonorrhea
CARB-X today announced an award of $1 million to Prompt Diagnostics LLC to develop a portable, rapid diagnostic test for antibiotic-resistant gonorrhea.
-
06.20.2024 | CRISPR technology’s next wave: Eight companies to watch in 2024
CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is a gene-editing technology that allows scientists to modify DNA with unprecedented precision. Discovered in the early 2010s, CRISPR technology leverages a natural defense mechanism used by bacteria to protect against viral infections.
-
06.14.2024 | AI enables faster, more effective antibiotic treatment of sepsis
Sepsis is a life-threatening infection complication and accounts for 1.7 million hospitalizations and 350,000 deaths annually in the U.S. Fast and accurate diagnosis is critical, as mortality risk increases up to 8% every hour without effective treatment.
-
06.12.2024 | New collaborative effort to combat multidrug-resistant infections with novel compound
The Global Antibiotic Research & Development Partnership (GARDP) and Bugworks Research Inc (Bugworks) have unveiled a collaboration agreement aimed at jointly developing an innovative compound (BWC0977). This compound exhibits broad-spectrum antibiotic activity against multidrug-resistant bacteria responsible for life-threatening infections.
-
06.11.2024 | GARDP commits $20 million for Bugworks’ molecule to fight MDR bacteria
Swiss not-for-profit organisation Global Antibiotic Research & Development Partnership (GARDP) will provide up to $20 million in technical and financial support for an innovative compound with broad-spectrum antibiotic activity biopharma firm Bugworks Research Inc. is developing against multidrug-resistant bacteria that cause life-threatening infections.
-
06.11.2024 | GARDP, Bugworks to collaborate on broad-spectrum antibiotic
The Global Antibiotic Research & Development Partnership (GARDP) today announced an agreement with Indian pharmaceutical company Bugworks Research Inc. to co-develop a new broad-spectrum antibiotic that targets some of the most difficult-to-treat bacterial pathogens.
-
06.07.2024 | A new synthetic antibiotic tightly binds bacterial ribosomes
The evolutionary arms race where bacteria evolve mechanisms to outsmart antibiotic drugs has left clinicians with a dearth of ways to fight bacterial infections effectively. To discover new antibiotics, researchers in chemist Andrew Myers’ laboratory at Harvard University turned to completely synthetic approaches.
-
06.04.2024 | Drug-resistant bacteria are killing more and more humans. We need new weapons.
The first antibiotics ushered in a medical revolution a century ago, saving millions of lives every year from deadly infections and allowing doctors to safely perform many medical procedures we now take for granted — simple and complex surgeries, chemotherapy, intensive care. People are living decades longer in the age of antibiotics than they did at the beginning of the 20th century.
-
05.28.2024 | Vaccine development program aims to prevent sepsis in newborns
University of Maryland School of Medicine (UMSOM) researchers at the Center for Vaccine Development and Global Health (CVD) have been awarded $3.96 million to develop a maternal vaccine that prevents sepsis caused by Klebsiella pneumoniae in newborns and infants.
-
05.21.2024 | Vedanta Biosciences enrolls first patient in pivotal phase 3 RESTORATiVE303 study of VE303 for the prevention of recurrent C. difficile Infection
Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, today announced that the first patient has been dosed in the global Phase 3 RESTORATiVE303 clinical study. VE303 is an orally administered defined bacterial consortium candidate that is being developed for the prevention of recurrent C. difficile infection (rCDI).
-
05.16.2024 | GSK, UK govt put £130m into antimicrobial resistance fight
GSK has become the first founding partner of the new Fleming Initiative, which aims to tackle the rising threat of antimicrobial resistance (AMR) and is also backed by the UK government.
-
05.15.2024 | Overcoming AMR market failure: Three start-up stories
Slowly but surely, the world’s antibiotics are becoming less effective as disease-causing bacteria evolve into drug-resistant “superbugs”. The crisis is inevitable, but there’s little short-term financial incentive to develop new antibiotics.
-
05.03.2024 | Multidrug-resistant “super gonorrhea” rallies multipronged effort
The clock is ticking on effective gonorrhea treatments—some say since 2018, when researchers in the UK reported the first Neisseria gonorrhoeae strain with resistance to ceftriaxone and high-level resistance to azithromycin, the first-line combination regimen at the time.
-
04.29.2024 | Denmark’s SNIPR Biome secures $5.48M funding from CARB-X for clinical trial of CRISPR therapy in cancer patients
SNIPR Biome, a Copanhagen-based clinical-stage biotech company pioneering precision medicines using CRISPR technology for microbial gene therapy, has secured $5.48 million in funding from the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) to co-fund a Phase 1b/2a clinical trial in hematological cancer patients.
-
04.27.2024 | Interview with Locus Biosciences CEO & Co-Founder Paul Garofolo
Locus Biosciences CEO & Co-Founder answers questions about the company, its goals and the impact it's having on the fight against antimicrobial resistance.
-
04.23.2024 | CARB-X grants funding to develop low-cost STI testing
Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) has announced it will award up to US$1 million to diagnostics and health technology company Scout to demonstrate proof-of-concept and feasibility ahead of development of a new point-of-care test – STI Scout.
-
04.22.2024 | CARB-X funds Scout to develop a low-cost point-of-care diagnostic for STI testing
Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) will award up to 1 million USD to diagnostics and health tech company Scout to demonstrate proof-of-concept and feasibility ahead of development of a new point-of-care test, STI Scout.
-
04.22.2024 | SNIPR Biome secures USD 5.5 million from CARB-X to advance clinical progress
CRISPR-based gene editing company SNIPR biome has secured USD 5.48 million from global non-profit partnership Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X).
-
04.22.2024 | SNIPR Biome receives funding from CARB-X to support advancement of CRISPR-medicine SNIPR001 into clinical trials in haematological cancer patients
SNIPR Biome ApS (“SNIPR”), the company pioneering the development of precision medicines using CRISPR technology for microbial gene therapy, announces today that it has received $5.48 million from Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (“CARB-X”) to co-fund a Phase 1b/2a clinical trial in hematological cancer patients.
-
04.22.2024 | SNIPR Biome secures funding from CARB-X to advance CRISPR medicine SNIPR001 into clinical trials for haematological cancer patients
SNIPR Biome ApS, a pioneer in precision medicine using CRISPR technology for microbial gene therapy, has secured $5.48 million from the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X). This funding will co-fund a Phase 1b/2a clinical trial in hematological cancer patients.
-
04.22.2024 | SNIPR Biome receives funding from CARB-X for advancement of SNIPR001 into clinical trials in haematological cancer patients
SNIPR Biome ApS (“SNIPR”), the company pioneering the development of precision medicines using CRISPR technology for microbial gene therapy, announces today that it has received $5.48 million from Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (“CARB-X”) to co-fund a Phase 1b/2a clinical trial in hematological cancer patients.
-
04.19.2024 | Low-cost point-of-care diagnostic to expand access to STI testing
Gonorrhea ranks as the second most commonly reported bacterial sexually transmitted infection (STI), with around 82 million global cases in 2020. The infection can lead to severe health consequences like pelvic inflammatory disease, chronic pelvic pain, and infertility.
-
04.19.2024 | Scout secures CARB-X grant to advance diagnostic test development
Scout, a diagnostics and health tech company, has received up to $1m in funding from the US non-profit organisation Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) to advance the development of a new point-of-care diagnostic test, STI Scout.
-
04.18.2024 | CARB-X funds development of POC home test for gonorrhea and chlamydia
CARB-X is awarding $1 million to diagnostics and health tech company Scout to develop a new point-of-care test that aims to detect and differentiate between Neisseria gonorrhoeae and Chlamydia trachomatis quickly and more affordably.
-
04.18.2024 | CARB-X funds development of rapid, affordable gonorrhea test
CARB-X announced today that it is awarding up to $1 million to diagnostics and health technology company Scout to develop a rapid and inexpensive point-of-care diagnostic test for gonorrhea that could be used at sexually transmitted infection (STI) clinics and urgent care centers.
-
04.18.2024 | Scout nabs $1M CARB-X award for point-of-care molecular STI test
Diagnostics developer Scout announced Thursday that it has been awarded $1 million in funding from the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X). The funding will support the development of Scout's point-of-care molecular diagnostic test for sexually transmitted infections.
-
04.18.2024 | Scout receives funding from CARB-X to develop a low-cost point-of-care and home diagnostic for gonorrhea and chlamydia
Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) will award up to US$1 million to diagnostics and health tech company Scout to demonstrate proof-of-concept and feasibility ahead of development of a new point-of-care test – STI Scout. The test will detect and differentiate between Neisseria gonorrhoeae (Ng) and Chlamydia trachomatis (Ct).
-
04.02.2024 | SNIPR Biome receives CARB-X funding to test SNIPR001 in phase 1B/2A clinical trial
Danish CRISPR company SNIPR Biome has received $5.48 million from Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (“CARB-X”) to co-fund a Phase 1b/2a clinical of SNIPR001 in blood cancer patients.
-
03.02.2024 | $467,000 funds maternal vaccine to prevent neonatal sepsis
Escherichia coli (E. coli) is a harmful bacteria that poses a severe threat to newborns, causing neonatal sepsis infections that can be life-threatening. Given the underdeveloped immune systems of newborns, they are particularly vulnerable to such infections.
-
03.01.2024 | Boston U accelerator funds vaccine for infant sepsis
CARB-X, a Boston University-led nonprofit that funds projects that focus on antimicrobial stewardship, awarded $467,000 to GlyProVac to develop a maternal vaccine that could prevent sepsis in infants, according to a Feb. 29 news release.
-
03.01.2024 | CARB-X funds development of novel vaccine for infant sepsis
CARB-X announced yesterday that it is awarding Danish research and development company GlyProVac $467,000 to develop a maternal vaccine that targets a leading cause of neonatal sepsis.
-
02.28.2024 | Swiss vaccine developer Limma Tech get CARB-X grant
Swiss multivalent vaccine developer LimmaTech Biologics AG has been awarded US$2.2m from the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X).
-
02.27.2024 | CARB-X announces funding for gonorrhea vaccine
CARB-X, the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator, announced it's giving $2.2 million to LimmaTech Biologics AG, a Swiss biotech firm, to fund the development of its novel vaccine candidate targeted to prevent Neisseria gonorrhoeae infections.
-
02.27.2024 | $2.2 Million award advances gonorrhea vaccine development
Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) today announced it awarded $2.2 million to LimmaTech Biologics AG to advance the development of its novel vaccine candidate targeted to prevent Neisseria gonorrhea (NG) infections.
-
02.21.2024 | Harvard’s new synthetic molecule highly effective against superbugs
A new antibiotic created by Harvard researchers overcomes antimicrobial resistance mechanisms that have rendered many modern drugs ineffective and are driving a global public health crisis.
-
02.19.2024 | Harvard researchers develop new antibiotic to prevent drug-resistant bacteria
In the fight against drug-resistant infections, researchers from Harvard have developed an antibiotic named cresomycin. This synthetic compound is capable of overcoming a growing global health menace posed by drug-resistant bacteria.
-
02.16.2024 | New synthetic molecule effective against superbugs
A synthetic antibiotic molecule can kill drug-resistant strains of superbugs such as Staphylococcus aureus and Pseudomonas aeruginosa. The research, by Harvard University scientists, is published in Science.
-
02.16.2024 | Antibiotic “preorganized” for ribosome binding overcomes superbugs
Researchers from Harvard University and elsewhere have created a synthetic antibiotic that is highly effective against antimicrobial resistance mechanisms that have stumped many modern antibiotics. Details of the design, synthesis, and evaluation of the antibiotic are provided in a new Science paper titled, “An antibiotic preorganized for ribosomal binding overcomes antimicrobial resistance.”
-
02.16.2024 | Revolutionary superbug killer could save millions from deadly infections
A game-changing superbug killer has been developed to combat drug-resistant bacteria. Called cresomycin, this innovative compound has shown promising results against strains of bacteria that are resistant to current medications.
-
02.15.2024 | Potential new weapon in battle against superbugs
Harvard researchers have created an antibiotic that can overcome many drug-resistant infections, which have become a growing, deadly global health menace.
-
02.15.2024 | Superbug killer: New synthetic molecule highly effective against drug-resistant bacteria
A new antibiotic created by Harvard researchers overcomes antimicrobial resistance mechanisms that have rendered many modern drugs ineffective and are driving a global public health crisis.
-
02.14.2024 | Harvard gets $1.2M to develop oral antibiotics that kill drug-resistant infections
Harvard University researchers have received $1.2 million from CARB-X, a Boston University-led nonprofit that funds projects that focus on drug-resistant bacteria named on the CDC’s Antibiotic Resistant Threats list.
-
01.17.2024 | ANTABIO raises €25 million for phase 2 next-gen antibacterial study
Antabio SAS, a clinical stage biopharmaceutical company developing novel treatments for severe drug-resistant bacterial infections, has raised €25 million in a Series B financing round, which will enable the company to complete the phase 2 clinical studies of MEM-ANT3310, a next generation antibacterial.
Toggle navigation